GSK is set to gain exclusive rights to first-in-class oral antifungal Brexafemme (ibrexafungerp) for treating vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC) from...
30.09.2014
- Dramatic changes to the scientific and business environments have made it impossible for pharmaceutical companies to continue operating as they have in the past. A perceived...
